nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—melanoma	0.819	1	CbGaD
Plerixafor—CXCR4—endothelium—melanoma	0.00769	0.266	CbGeAlD
Plerixafor—CXCR4—blood vessel—melanoma	0.0071	0.245	CbGeAlD
Plerixafor—CXCR4—eye—melanoma	0.00378	0.13	CbGeAlD
Plerixafor—CXCR4—retina—melanoma	0.00374	0.129	CbGeAlD
Plerixafor—CXCR4—mammalian vulva—melanoma	0.003	0.104	CbGeAlD
Plerixafor—CXCR4—head—melanoma	0.00214	0.0741	CbGeAlD
Plerixafor—Induration—Bleomycin—melanoma	0.00178	0.041	CcSEcCtD
Plerixafor—CXCR4—lymph node—melanoma	0.0015	0.0519	CbGeAlD
Plerixafor—Musculoskeletal pain—Vemurafenib—melanoma	0.00133	0.0306	CcSEcCtD
Plerixafor—Injection site reaction—Carmustine—melanoma	0.00069	0.0159	CcSEcCtD
Plerixafor—Musculoskeletal pain—Temozolomide—melanoma	0.000679	0.0157	CcSEcCtD
Plerixafor—Connective tissue disorder—Vemurafenib—melanoma	0.000648	0.0149	CcSEcCtD
Plerixafor—Erythema—Vemurafenib—melanoma	0.000574	0.0132	CcSEcCtD
Plerixafor—Swelling—Carmustine—melanoma	0.000571	0.0132	CcSEcCtD
Plerixafor—Arthralgia—Vemurafenib—melanoma	0.000489	0.0113	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000485	0.0112	CcSEcCtD
Plerixafor—Anaphylactic shock—Vemurafenib—melanoma	0.000468	0.0108	CcSEcCtD
Plerixafor—Inflammation—Docetaxel—melanoma	0.00046	0.0106	CcSEcCtD
Plerixafor—Nervous system disorder—Vemurafenib—melanoma	0.000459	0.0106	CcSEcCtD
Plerixafor—Skin disorder—Vemurafenib—melanoma	0.000455	0.0105	CcSEcCtD
Plerixafor—Injection site reaction—Docetaxel—melanoma	0.000444	0.0102	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000427	0.00984	CcSEcCtD
Plerixafor—Abdominal distension—Temozolomide—melanoma	0.000424	0.00977	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Vemurafenib—melanoma	0.000404	0.00932	CcSEcCtD
Plerixafor—Fatigue—Vemurafenib—melanoma	0.000404	0.00931	CcSEcCtD
Plerixafor—Haemoglobin—Bleomycin—melanoma	0.000401	0.00925	CcSEcCtD
Plerixafor—Constipation—Vemurafenib—melanoma	0.000401	0.00923	CcSEcCtD
Plerixafor—Haemorrhage—Bleomycin—melanoma	0.000399	0.00921	CcSEcCtD
Plerixafor—Swelling—Docetaxel—melanoma	0.000367	0.00846	CcSEcCtD
Plerixafor—Haemoglobin—Carmustine—melanoma	0.00035	0.00808	CcSEcCtD
Plerixafor—Haemorrhage—Carmustine—melanoma	0.000349	0.00804	CcSEcCtD
Plerixafor—Erythema—Bleomycin—melanoma	0.000348	0.00801	CcSEcCtD
Plerixafor—Hypersensitivity—Vemurafenib—melanoma	0.000345	0.00795	CcSEcCtD
Plerixafor—Connective tissue disorder—Carmustine—melanoma	0.000343	0.0079	CcSEcCtD
Plerixafor—Haemoglobin—Temozolomide—melanoma	0.000339	0.0078	CcSEcCtD
Plerixafor—Haemorrhage—Temozolomide—melanoma	0.000337	0.00777	CcSEcCtD
Plerixafor—Asthenia—Vemurafenib—melanoma	0.000336	0.00775	CcSEcCtD
Plerixafor—Pruritus—Vemurafenib—melanoma	0.000331	0.00764	CcSEcCtD
Plerixafor—Connective tissue disorder—Temozolomide—melanoma	0.000331	0.00763	CcSEcCtD
Plerixafor—Erythema—Dactinomycin—melanoma	0.000324	0.00747	CcSEcCtD
Plerixafor—Ill-defined disorder—Bleomycin—melanoma	0.000323	0.00744	CcSEcCtD
Plerixafor—Diarrhoea—Vemurafenib—melanoma	0.00032	0.00739	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—TAS2R60—melanoma	0.000315	0.00288	CbGpPWpGaD
Plerixafor—Malaise—Bleomycin—melanoma	0.000314	0.00723	CcSEcCtD
Plerixafor—CXCR4—Disease—MYO7A—melanoma	0.000312	0.00286	CbGpPWpGaD
Plerixafor—Dizziness—Vemurafenib—melanoma	0.00031	0.00714	CcSEcCtD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL6—melanoma	0.000309	0.00283	CbGpPWpGaD
Plerixafor—Mental disorder—Carmustine—melanoma	0.000305	0.00704	CcSEcCtD
Plerixafor—Immune system disorder—Temozolomide—melanoma	0.000304	0.00701	CcSEcCtD
Plerixafor—Erythema—Carmustine—melanoma	0.000303	0.007	CcSEcCtD
Plerixafor—Ill-defined disorder—Dactinomycin—melanoma	0.000301	0.00693	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—melanoma	0.0003	0.00274	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.000298	0.00273	CbGpPWpGaD
Plerixafor—Vomiting—Vemurafenib—melanoma	0.000298	0.00686	CcSEcCtD
Plerixafor—Orthostatic hypotension—Docetaxel—melanoma	0.000296	0.00682	CcSEcCtD
Plerixafor—Rash—Vemurafenib—melanoma	0.000295	0.00681	CcSEcCtD
Plerixafor—Mental disorder—Temozolomide—melanoma	0.000295	0.0068	CcSEcCtD
Plerixafor—Dermatitis—Vemurafenib—melanoma	0.000295	0.0068	CcSEcCtD
Plerixafor—Headache—Vemurafenib—melanoma	0.000293	0.00676	CcSEcCtD
Plerixafor—Erythema—Temozolomide—melanoma	0.000293	0.00676	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—EDN1—melanoma	0.000293	0.00268	CbGpPWpGaD
Plerixafor—Discomfort—Bleomycin—melanoma	0.000292	0.00674	CcSEcCtD
Plerixafor—Malaise—Dactinomycin—melanoma	0.000292	0.00674	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.000289	0.00264	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Bleomycin—melanoma	0.000284	0.00654	CcSEcCtD
Plerixafor—Nausea—Vemurafenib—melanoma	0.000278	0.00641	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—melanoma	0.000275	0.00252	CbGpPWpGaD
Plerixafor—Discomfort—Dactinomycin—melanoma	0.000273	0.00629	CcSEcCtD
Plerixafor—Ill-defined disorder—Temozolomide—melanoma	0.000272	0.00627	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CXCR2—melanoma	0.000267	0.00244	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HS3ST5—melanoma	0.000265	0.00243	CbGpPWpGaD
Plerixafor—Malaise—Temozolomide—melanoma	0.000264	0.0061	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL1—melanoma	0.000263	0.00241	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PLCB4—melanoma	0.000263	0.00241	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Bleomycin—melanoma	0.000259	0.00596	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—WNT5A—melanoma	0.000258	0.00237	CbGpPWpGaD
Plerixafor—Paraesthesia—Bleomycin—melanoma	0.000255	0.00587	CcSEcCtD
Plerixafor—Dyspnoea—Bleomycin—melanoma	0.000253	0.00583	CcSEcCtD
Plerixafor—Arthralgia—Temozolomide—melanoma	0.00025	0.00576	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000248	0.00572	CcSEcCtD
Plerixafor—Discomfort—Temozolomide—melanoma	0.000247	0.00569	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—ERCC2—melanoma	0.000246	0.00225	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—melanoma	0.000245	0.00224	CbGpPWpGaD
Plerixafor—Dry mouth—Temozolomide—melanoma	0.000244	0.00563	CcSEcCtD
Plerixafor—Pain—Bleomycin—melanoma	0.000243	0.00559	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000241	0.00556	CcSEcCtD
Plerixafor—Anaphylactic shock—Temozolomide—melanoma	0.000239	0.00552	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PLCB4—melanoma	0.000238	0.00218	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CXCL1—melanoma	0.000238	0.00218	CbGpPWpGaD
Plerixafor—Nervous system disorder—Temozolomide—melanoma	0.000235	0.00541	CcSEcCtD
Plerixafor—Feeling abnormal—Bleomycin—melanoma	0.000234	0.00539	CcSEcCtD
Plerixafor—Skin disorder—Temozolomide—melanoma	0.000233	0.00536	CcSEcCtD
Plerixafor—Hyperhidrosis—Temozolomide—melanoma	0.000231	0.00533	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—HLA-A—melanoma	0.00023	0.00211	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—RAC1—melanoma	0.00023	0.0021	CbGpPWpGaD
Plerixafor—Fatigue—Dactinomycin—melanoma	0.000228	0.00526	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—F2R—melanoma	0.000227	0.00208	CbGpPWpGaD
Plerixafor—Pain—Dactinomycin—melanoma	0.000226	0.00522	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Carmustine—melanoma	0.000226	0.0052	CcSEcCtD
Plerixafor—Urticaria—Bleomycin—melanoma	0.000225	0.0052	CcSEcCtD
Plerixafor—Haemoglobin—Docetaxel—melanoma	0.000225	0.00519	CcSEcCtD
Plerixafor—Haemorrhage—Docetaxel—melanoma	0.000224	0.00516	CcSEcCtD
Plerixafor—Insomnia—Carmustine—melanoma	0.000224	0.00516	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—F2RL1—melanoma	0.000223	0.00204	CbGpPWpGaD
Plerixafor—Paraesthesia—Carmustine—melanoma	0.000222	0.00513	CcSEcCtD
Plerixafor—Dyspnoea—Carmustine—melanoma	0.000221	0.00509	CcSEcCtD
Plerixafor—Connective tissue disorder—Docetaxel—melanoma	0.00022	0.00507	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—EDNRB—melanoma	0.00022	0.00201	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—DRAP1—melanoma	0.000219	0.002	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYO7A—melanoma	0.000219	0.002	CbGpPWpGaD
Plerixafor—Feeling abnormal—Dactinomycin—melanoma	0.000218	0.00503	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Temozolomide—melanoma	0.000218	0.00503	CcSEcCtD
Plerixafor—Insomnia—Temozolomide—melanoma	0.000216	0.00499	CcSEcCtD
Plerixafor—Gastrointestinal pain—Dactinomycin—melanoma	0.000216	0.00499	CcSEcCtD
Plerixafor—Paraesthesia—Temozolomide—melanoma	0.000215	0.00495	CcSEcCtD
Plerixafor—CXCR4—HIV Life Cycle—CD4—melanoma	0.000215	0.00197	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Carmustine—melanoma	0.000214	0.00493	CcSEcCtD
Plerixafor—Dyspnoea—Temozolomide—melanoma	0.000213	0.00492	CcSEcCtD
Plerixafor—Pain—Carmustine—melanoma	0.000212	0.00488	CcSEcCtD
Plerixafor—Constipation—Carmustine—melanoma	0.000212	0.00488	CcSEcCtD
Plerixafor—Dyspepsia—Temozolomide—melanoma	0.000211	0.00486	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—GRM3—melanoma	0.00021	0.00192	CbGpPWpGaD
Plerixafor—Abdominal pain—Dactinomycin—melanoma	0.000209	0.00482	CcSEcCtD
Plerixafor—Hypersensitivity—Bleomycin—melanoma	0.000209	0.00482	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Temozolomide—melanoma	0.000207	0.00476	CcSEcCtD
Plerixafor—Fatigue—Temozolomide—melanoma	0.000206	0.00476	CcSEcCtD
Plerixafor—Constipation—Temozolomide—melanoma	0.000205	0.00472	CcSEcCtD
Plerixafor—Pain—Temozolomide—melanoma	0.000205	0.00472	CcSEcCtD
Plerixafor—Feeling abnormal—Carmustine—melanoma	0.000204	0.0047	CcSEcCtD
Plerixafor—Asthenia—Bleomycin—melanoma	0.000204	0.00469	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—F2RL1—melanoma	0.000203	0.00186	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Carmustine—melanoma	0.000203	0.00467	CcSEcCtD
Plerixafor—Immune system disorder—Docetaxel—melanoma	0.000202	0.00466	CcSEcCtD
Plerixafor—Pruritus—Bleomycin—melanoma	0.000201	0.00463	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—KISS1—melanoma	0.000199	0.00182	CbGpPWpGaD
Plerixafor—Feeling abnormal—Temozolomide—melanoma	0.000197	0.00455	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.000196	0.0018	CbGpPWpGaD
Plerixafor—Mental disorder—Docetaxel—melanoma	0.000196	0.00452	CcSEcCtD
Plerixafor—Abdominal pain—Carmustine—melanoma	0.000196	0.00451	CcSEcCtD
Plerixafor—Gastrointestinal pain—Temozolomide—melanoma	0.000196	0.00451	CcSEcCtD
Plerixafor—Erythema—Docetaxel—melanoma	0.000195	0.0045	CcSEcCtD
Plerixafor—Hypersensitivity—Dactinomycin—melanoma	0.000195	0.00449	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CA—melanoma	0.000193	0.00177	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CXCR1—melanoma	0.000193	0.00177	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—melanoma	0.000191	0.00175	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GRM3—melanoma	0.000191	0.00175	CbGpPWpGaD
Plerixafor—Urticaria—Temozolomide—melanoma	0.00019	0.00438	CcSEcCtD
Plerixafor—Asthenia—Dactinomycin—melanoma	0.00019	0.00438	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—MC1R—melanoma	0.00019	0.00174	CbGpPWpGaD
Plerixafor—Abdominal pain—Temozolomide—melanoma	0.000189	0.00436	CcSEcCtD
Plerixafor—CXCR4—Disease—TRRAP—melanoma	0.000189	0.00173	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CUL3—melanoma	0.000189	0.00173	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TAS2R60—melanoma	0.000186	0.0017	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKR1B10—melanoma	0.000184	0.00169	CbGpPWpGaD
Plerixafor—Hypersensitivity—Carmustine—melanoma	0.000182	0.00421	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CCR7—melanoma	0.000182	0.00167	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GRM1—melanoma	0.000182	0.00167	CbGpPWpGaD
Plerixafor—Diarrhoea—Dactinomycin—melanoma	0.000181	0.00417	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—KISS1—melanoma	0.000181	0.00166	CbGpPWpGaD
Plerixafor—Vomiting—Bleomycin—melanoma	0.00018	0.00416	CcSEcCtD
Plerixafor—Rash—Bleomycin—melanoma	0.000179	0.00412	CcSEcCtD
Plerixafor—Dermatitis—Bleomycin—melanoma	0.000179	0.00412	CcSEcCtD
Plerixafor—Asthenia—Carmustine—melanoma	0.000178	0.0041	CcSEcCtD
Plerixafor—Hypersensitivity—Temozolomide—melanoma	0.000176	0.00406	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CXCR1—melanoma	0.000175	0.0016	CbGpPWpGaD
Plerixafor—Syncope—Docetaxel—melanoma	0.000175	0.00403	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—MC1R—melanoma	0.000172	0.00158	CbGpPWpGaD
Plerixafor—Asthenia—Temozolomide—melanoma	0.000172	0.00396	CcSEcCtD
Plerixafor—Loss of consciousness—Docetaxel—melanoma	0.000171	0.00395	CcSEcCtD
Plerixafor—Diarrhoea—Carmustine—melanoma	0.000169	0.00391	CcSEcCtD
Plerixafor—Pruritus—Temozolomide—melanoma	0.000169	0.0039	CcSEcCtD
Plerixafor—Nausea—Bleomycin—melanoma	0.000169	0.00388	CcSEcCtD
Plerixafor—Vomiting—Dactinomycin—melanoma	0.000168	0.00388	CcSEcCtD
Plerixafor—Rash—Dactinomycin—melanoma	0.000167	0.00385	CcSEcCtD
Plerixafor—Arthralgia—Docetaxel—melanoma	0.000166	0.00383	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—RHOB—melanoma	0.000166	0.00152	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GRM1—melanoma	0.000165	0.00151	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCR7—melanoma	0.000165	0.00151	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000165	0.0038	CcSEcCtD
Plerixafor—CXCR4—Disease—LUM—melanoma	0.000164	0.0015	CbGpPWpGaD
Plerixafor—Dizziness—Carmustine—melanoma	0.000164	0.00378	CcSEcCtD
Plerixafor—Diarrhoea—Temozolomide—melanoma	0.000164	0.00377	CcSEcCtD
Plerixafor—Dry mouth—Docetaxel—melanoma	0.000162	0.00374	CcSEcCtD
Plerixafor—CXCR4—Disease—HPSE—melanoma	0.000161	0.00147	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Docetaxel—melanoma	0.000159	0.00367	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—melanoma	0.000158	0.00145	CbGpPWpGaD
Plerixafor—Dizziness—Temozolomide—melanoma	0.000158	0.00365	CcSEcCtD
Plerixafor—CXCR4—Disease—CUBN—melanoma	0.000158	0.00145	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—melanoma	0.000158	0.00144	CbGpPWpGaD
Plerixafor—Vomiting—Carmustine—melanoma	0.000157	0.00363	CcSEcCtD
Plerixafor—Nausea—Dactinomycin—melanoma	0.000157	0.00362	CcSEcCtD
Plerixafor—Shock—Docetaxel—melanoma	0.000157	0.00361	CcSEcCtD
Plerixafor—Rash—Carmustine—melanoma	0.000156	0.0036	CcSEcCtD
Plerixafor—Nervous system disorder—Docetaxel—melanoma	0.000156	0.0036	CcSEcCtD
Plerixafor—Dermatitis—Carmustine—melanoma	0.000156	0.0036	CcSEcCtD
Plerixafor—Headache—Carmustine—melanoma	0.000155	0.00358	CcSEcCtD
Plerixafor—Skin disorder—Docetaxel—melanoma	0.000155	0.00356	CcSEcCtD
Plerixafor—CXCR4—Disease—CSPG4—melanoma	0.000152	0.0014	CbGpPWpGaD
Plerixafor—Vomiting—Temozolomide—melanoma	0.000152	0.00351	CcSEcCtD
Plerixafor—Rash—Temozolomide—melanoma	0.000151	0.00348	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CXCR2—melanoma	0.000151	0.00138	CbGpPWpGaD
Plerixafor—Dermatitis—Temozolomide—melanoma	0.000151	0.00348	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—RHOB—melanoma	0.00015	0.00138	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RPS3—melanoma	0.00015	0.00137	CbGpPWpGaD
Plerixafor—Headache—Temozolomide—melanoma	0.00015	0.00346	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—EDN1—melanoma	0.00015	0.00137	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—CD4—melanoma	0.000148	0.00136	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—RAC2—melanoma	0.000148	0.00136	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SKI—melanoma	0.000148	0.00135	CbGpPWpGaD
Plerixafor—Nausea—Carmustine—melanoma	0.000147	0.00339	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Docetaxel—melanoma	0.000145	0.00334	CcSEcCtD
Plerixafor—Insomnia—Docetaxel—melanoma	0.000144	0.00332	CcSEcCtD
Plerixafor—Paraesthesia—Docetaxel—melanoma	0.000143	0.00329	CcSEcCtD
Plerixafor—Nausea—Temozolomide—melanoma	0.000142	0.00328	CcSEcCtD
Plerixafor—Dyspnoea—Docetaxel—melanoma	0.000142	0.00327	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PLCB4—melanoma	0.000141	0.00129	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL1—melanoma	0.000141	0.00129	CbGpPWpGaD
Plerixafor—Dyspepsia—Docetaxel—melanoma	0.00014	0.00323	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Docetaxel—melanoma	0.000137	0.00317	CcSEcCtD
Plerixafor—Fatigue—Docetaxel—melanoma	0.000137	0.00316	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CXCR2—melanoma	0.000137	0.00125	CbGpPWpGaD
Plerixafor—Pain—Docetaxel—melanoma	0.000136	0.00314	CcSEcCtD
Plerixafor—Constipation—Docetaxel—melanoma	0.000136	0.00314	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—RAC2—melanoma	0.000135	0.00123	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—melanoma	0.000134	0.00122	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—WNT5A—melanoma	0.000133	0.00121	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CUL3—melanoma	0.000132	0.00121	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TRRAP—melanoma	0.000132	0.00121	CbGpPWpGaD
Plerixafor—Feeling abnormal—Docetaxel—melanoma	0.000131	0.00302	CcSEcCtD
Plerixafor—Gastrointestinal pain—Docetaxel—melanoma	0.00013	0.003	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AKR1B10—melanoma	0.000129	0.00118	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—F2R—melanoma	0.000128	0.00117	CbGpPWpGaD
Plerixafor—Abdominal pain—Docetaxel—melanoma	0.000126	0.0029	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—EDNRB—melanoma	0.000124	0.00114	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HDAC6—melanoma	0.000122	0.00112	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—F2RL1—melanoma	0.00012	0.0011	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GNA11—melanoma	0.000117	0.00107	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GAB2—melanoma	0.000117	0.00107	CbGpPWpGaD
Plerixafor—Hypersensitivity—Docetaxel—melanoma	0.000117	0.0027	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—F2R—melanoma	0.000116	0.00107	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NPPA—melanoma	0.000116	0.00106	CbGpPWpGaD
Plerixafor—Asthenia—Docetaxel—melanoma	0.000114	0.00263	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—EDNRB—melanoma	0.000113	0.00103	CbGpPWpGaD
Plerixafor—CXCR4—Disease—VCAN—melanoma	0.000113	0.00103	CbGpPWpGaD
Plerixafor—Pruritus—Docetaxel—melanoma	0.000113	0.0026	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GRM3—melanoma	0.000113	0.00103	CbGpPWpGaD
Plerixafor—CXCR4—Disease—WNT5A—melanoma	0.000112	0.00102	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GNAQ—melanoma	0.000109	0.000999	CbGpPWpGaD
Plerixafor—Diarrhoea—Docetaxel—melanoma	0.000109	0.00251	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—KISS1—melanoma	0.000107	0.000978	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GAB2—melanoma	0.000107	0.000976	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GNA11—melanoma	0.000107	0.000976	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000106	0.000973	CbGpPWpGaD
Plerixafor—Dizziness—Docetaxel—melanoma	0.000105	0.00243	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SKI—melanoma	0.000103	0.000947	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCR1—melanoma	0.000103	0.000947	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MC1R—melanoma	0.000102	0.000933	CbGpPWpGaD
Plerixafor—Vomiting—Docetaxel—melanoma	0.000101	0.00233	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—AKT3—melanoma	0.000101	0.000922	CbGpPWpGaD
Plerixafor—Rash—Docetaxel—melanoma	0.0001	0.00231	CcSEcCtD
Plerixafor—Dermatitis—Docetaxel—melanoma	0.0001	0.00231	CcSEcCtD
Plerixafor—Headache—Docetaxel—melanoma	9.97e-05	0.0023	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—GNAQ—melanoma	9.9e-05	0.000907	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCR7—melanoma	9.76e-05	0.000894	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GRM1—melanoma	9.76e-05	0.000894	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SUFU—melanoma	9.51e-05	0.000871	CbGpPWpGaD
Plerixafor—Nausea—Docetaxel—melanoma	9.46e-05	0.00218	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—AKT3—melanoma	9.14e-05	0.000837	CbGpPWpGaD
Plerixafor—CXCR4—Disease—GAB2—melanoma	8.98e-05	0.000823	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BCL2L11—melanoma	8.88e-05	0.000814	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RHOB—melanoma	8.88e-05	0.000814	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FASN—melanoma	8.79e-05	0.000805	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HDAC6—melanoma	8.53e-05	0.000782	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—EDN1—melanoma	8.45e-05	0.000774	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HDAC2—melanoma	8.45e-05	0.000774	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FOXO4—melanoma	8.45e-05	0.000774	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD44—melanoma	8.35e-05	0.000765	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CSF2—melanoma	8.26e-05	0.000757	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCR2—melanoma	8.09e-05	0.000741	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—melanoma	8.09e-05	0.000741	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RAC2—melanoma	7.96e-05	0.000729	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PRKCA—melanoma	7.92e-05	0.000726	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—WNT5A—melanoma	7.84e-05	0.000718	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFC—melanoma	7.84e-05	0.000718	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT3—melanoma	7.71e-05	0.000706	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EDN1—melanoma	7.68e-05	0.000703	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CSF2—melanoma	7.5e-05	0.000687	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—RAC1—melanoma	7.34e-05	0.000673	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PRKCA—melanoma	7.19e-05	0.000659	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAP2K2—melanoma	7.03e-05	0.000644	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—F2R—melanoma	6.88e-05	0.00063	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB4—melanoma	6.81e-05	0.000624	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN2B—melanoma	6.75e-05	0.000618	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—RAC1—melanoma	6.67e-05	0.000611	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EDNRB—melanoma	6.66e-05	0.00061	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD86—melanoma	6.53e-05	0.000598	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTK2B—melanoma	6.47e-05	0.000592	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGF1—melanoma	6.33e-05	0.00058	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GAB2—melanoma	6.29e-05	0.000576	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GNA11—melanoma	6.29e-05	0.000576	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FLT1—melanoma	6.26e-05	0.000574	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—melanoma	6.21e-05	0.000568	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PDGFRA—melanoma	6.13e-05	0.000562	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PRKCA—melanoma	6.07e-05	0.000556	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERCC2—melanoma	6.02e-05	0.000551	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAP2K2—melanoma	5.93e-05	0.000543	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FOXO4—melanoma	5.92e-05	0.000542	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HDAC2—melanoma	5.92e-05	0.000542	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GNAQ—melanoma	5.85e-05	0.000536	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TERT—melanoma	5.64e-05	0.000517	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HLA-A—melanoma	5.64e-05	0.000517	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—melanoma	5.64e-05	0.000516	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RAC1—melanoma	5.63e-05	0.000515	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SYK—melanoma	5.5e-05	0.000504	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CD—melanoma	5.46e-05	0.0005	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT3—melanoma	5.4e-05	0.000494	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ITGAV—melanoma	5.4e-05	0.000494	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NGFR—melanoma	5.4e-05	0.000494	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HIF1A—melanoma	5.4e-05	0.000494	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SOCS1—melanoma	5e-05	0.000458	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAP2K1—melanoma	4.99e-05	0.000457	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—S100B—melanoma	4.99e-05	0.000457	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CD—melanoma	4.95e-05	0.000454	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOS2—melanoma	4.91e-05	0.00045	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOTCH1—melanoma	4.86e-05	0.000445	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB4—melanoma	4.77e-05	0.000437	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD80—melanoma	4.76e-05	0.000436	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CB—melanoma	4.75e-05	0.000436	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APC—melanoma	4.75e-05	0.000435	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KIT—melanoma	4.75e-05	0.000435	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN2B—melanoma	4.73e-05	0.000433	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGF—melanoma	4.7e-05	0.00043	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CD86—melanoma	4.57e-05	0.000419	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—melanoma	4.57e-05	0.000419	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EDN1—melanoma	4.54e-05	0.000415	CbGpPWpGaD
Plerixafor—CXCR4—Disease—BRAF—melanoma	4.47e-05	0.000409	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CSF2—melanoma	4.43e-05	0.000406	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGF1—melanoma	4.43e-05	0.000406	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—melanoma	4.37e-05	0.0004	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—E2F1—melanoma	4.34e-05	0.000397	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CB—melanoma	4.32e-05	0.000395	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PDGFRA—melanoma	4.29e-05	0.000393	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ITGB3—melanoma	4.25e-05	0.000389	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PRKCA—melanoma	4.25e-05	0.000389	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAP2K1—melanoma	4.21e-05	0.000385	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CD—melanoma	4.18e-05	0.000383	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SPP1—melanoma	4.17e-05	0.000382	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAP2K2—melanoma	4.15e-05	0.000381	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—melanoma	4.15e-05	0.00038	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGF2—melanoma	4e-05	0.000366	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL2—melanoma	3.97e-05	0.000363	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—melanoma	3.95e-05	0.000362	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RAC1—melanoma	3.94e-05	0.000361	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HIF1A—melanoma	3.78e-05	0.000346	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MDM2—melanoma	3.74e-05	0.000343	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB2—melanoma	3.69e-05	0.000338	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CB—melanoma	3.64e-05	0.000334	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD4—melanoma	3.64e-05	0.000333	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KDR—melanoma	3.61e-05	0.000331	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—melanoma	3.61e-05	0.000331	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FN1—melanoma	3.48e-05	0.000319	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1B—melanoma	3.42e-05	0.000313	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH1—melanoma	3.4e-05	0.000312	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CD80—melanoma	3.33e-05	0.000305	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—melanoma	3.33e-05	0.000305	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APC—melanoma	3.33e-05	0.000305	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KIT—melanoma	3.33e-05	0.000305	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—melanoma	3.33e-05	0.000305	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGF—melanoma	3.29e-05	0.000301	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—melanoma	3.23e-05	0.000296	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK3—melanoma	3.19e-05	0.000292	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1A—melanoma	3.15e-05	0.000289	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—melanoma	3.15e-05	0.000288	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BRAF—melanoma	3.13e-05	0.000287	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1—melanoma	3.05e-05	0.000279	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK1—melanoma	3.03e-05	0.000278	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—melanoma	3.03e-05	0.000278	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAP2K1—melanoma	2.95e-05	0.00027	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CD—melanoma	2.93e-05	0.000268	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—melanoma	2.9e-05	0.000265	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—melanoma	2.87e-05	0.000262	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—melanoma	2.81e-05	0.000258	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRAS—melanoma	2.81e-05	0.000257	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGF2—melanoma	2.8e-05	0.000257	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK3—melanoma	2.69e-05	0.000246	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—melanoma	2.63e-05	0.000241	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MDM2—melanoma	2.62e-05	0.00024	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—melanoma	2.62e-05	0.00024	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB2—melanoma	2.58e-05	0.000237	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK1—melanoma	2.56e-05	0.000234	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—melanoma	2.56e-05	0.000234	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CB—melanoma	2.55e-05	0.000234	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—melanoma	2.45e-05	0.000225	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—melanoma	2.44e-05	0.000223	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—melanoma	2.42e-05	0.000221	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1B—melanoma	2.39e-05	0.000219	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—melanoma	2.37e-05	0.000217	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—melanoma	2.35e-05	0.000215	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—melanoma	2.34e-05	0.000215	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—melanoma	2.33e-05	0.000213	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—melanoma	2.28e-05	0.000209	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—melanoma	2.26e-05	0.000207	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—melanoma	2.22e-05	0.000203	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—melanoma	2.22e-05	0.000203	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1A—melanoma	2.21e-05	0.000202	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—melanoma	2.2e-05	0.000202	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NFKB1—melanoma	2.19e-05	0.000201	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—melanoma	2.15e-05	0.000197	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—melanoma	2.05e-05	0.000188	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—melanoma	1.99e-05	0.000182	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—melanoma	1.97e-05	0.000181	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—melanoma	1.97e-05	0.00018	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—melanoma	1.97e-05	0.00018	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK3—melanoma	1.88e-05	0.000172	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—melanoma	1.83e-05	0.000168	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—melanoma	1.81e-05	0.000166	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK1—melanoma	1.79e-05	0.000164	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGFR—melanoma	1.79e-05	0.000164	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—melanoma	1.69e-05	0.000155	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—melanoma	1.55e-05	0.000142	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—melanoma	1.5e-05	0.000138	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—melanoma	1.44e-05	0.000132	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—melanoma	1.38e-05	0.000126	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—melanoma	1.27e-05	0.000116	CbGpPWpGaD
